雷公藤多苷治疗IgA肾病患者的临床研究  

Clinical trial of tripterygium wilfordii polyglycoside in the treatment of patients with IgA nephropathy

作　　者：沈世忠[1] 杨忠民[1] 蔡佳盈[1] 孙凌云[1] 胡义阳[1] 王捷 

机构地区：[1]福建医科大学附属泉州第一医院肾内科,福建泉州362000

出　　处：《中国临床药理学杂志》2017年第19期1878-1881,共4页The Chinese Journal of Clinical Pharmacology

基　　金：泉州市科技计划基金资助项目(2014Z66)

摘　　要：目的研究雷公藤多苷治疗IgA肾病患者的临床疗效。方法将40例IgA肾病患者视为试验组,用雷公藤多苷1 mg·kg^(-1)·d^(-1),分3次口服,治疗6个月。另取同期在本院进行健康体检的40例研究对象作为对照组,对照组不做任何处理。用酶联免疫吸附法检测2组患者血清白细胞介素-15(IL-15)、白细胞介素-18(IL-18)水平。分析患者临床疗效,测定2组研究对象血脂及24h尿蛋白沉淀定量指标。结果治疗后,试验组的总有效率达90.00%(36/40例)。治疗前,试验组与对照组的血清IL-15、IL-18水平分别为(79.47±7.46),(344.14±21.49)ng·L^(-1);(61.91±4.88),(95.70±6.78)ng·L^(-1),与对照组比较,差异均有统计学意义(均P<0.05)。治疗后,试验组的血清IL-15、IL-18水平分别为(61.76±6.98),(94.49±8.73)ng·L^(-1),与对照组比较,差异均无统计学意义(均P>0.05)。治疗前,试验组与对照组的尿红细胞计数、24 h尿蛋白定量分别为(153.00±10.33),(101.30±7.67)per·μL^(-1);(1.99±0.17),(0.48±0.04)g·d^(-1)。对照组比较,差异均有统计学意义(均P<0.05)。治疗后,试验组的尿红细胞计数、24 h尿蛋白定量分别为(103.16±7.54)per·μL^(-1),(0.51±0.04)g·d^(-1)。与治疗前相比,差异均有统计学意义(均P<0.05);与对照组相比,差异均无统计学意义(均P>0.05)。结论雷公藤多苷用于IgA肾病患者中,能有效降低患者血清的IL-15、IL-18水平,改善患者临床症状,且安全性良好。Objective To study the clinical efficacy of tripterygium glycosides in the treatment of IgA nephropathy. Methods Forty patients with IgA nephropathy admitted were enrolled in this study. The patient were treated with tripterygium glycosides 1 mg·kg^-1·d^-1,three times orally,were treated for 6 months. Another 40 healthy subjects in the hospital for the same period as the control group,the control group did not do any treatment. Serum interleukin-15（ IL-15） and interleukin-18（ IL-18） levels were measured by enzyme-linked immunosorbent assay（ ELISA）. The clinical efficacy of the patients was analyzed,and the quantitative indexes of blood lipid and 24 h urine protein were determined. Results After treatment,the total effective rate of the treatment group was 90. 00%（ 36/40 cases）. Before treatment,the levels of serum IL-15 and IL-18 in the treatment group and the control group were（ 79. 47 ± 7. 46）,（ 344. 14 ± 21. 49） ng · L^-1;（ 61. 91 ± 4. 88）,（ 95. 70 ± 6. 78） ng · L^-1. Compared with the control group, thedifference was statistically significant（ all P〈0. 05）. After treatment,the levels of serum IL-15 and IL-18 in the treatment group was（ 61. 76 ± 6. 98） and（ 94. 49 ± 8. 73） ng·L^-1respectively,compared with control group,there was no significant difference between the two groups（ P〈0. 05）. Before treatment,urine red blood cell（ RBC） count and 24 h urinary protein in the treatment group and the control group were（ 153. 00 ± 10. 33）,（ 101. 30 ± 7. 67）per·μL^-1;（ 1. 99 ± 0. 17）,（ 0. 48 ± 0. 04） g · d^-1. Compared with the control group,the differences were statistically significant（ all P〈0. 05）. After treatment,urine RBC count and 24 h urinary protein in the treatment group were（ 103. 16 ± 7. 54） per · μL^-1,（ 0. 51 ± 0. 04） g·d^-1. Compared with before treatment,the differences were statistically significant（ all P〈0. 05）. Compared with the control group,the difference was not statistically signific

关 键 词：雷公藤多苷 IGA肾病 白细胞介素-15 白细胞介素-18 

分 类 号：R28[医药卫生—中药学]